PCMC
CORT icon

Planning Capital Management Corporation’s Corcept Therapeutics CORT Stock Holding History

Planning Capital Management Corporation’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$50.9K Sell
1,100
-2,000
-65% -$71.1K 0.03% 179
2024
Q2 		$101K Hold
3,100
– – 0.07% 136
2024
Q1 		$78.1K Hold
3,100
– – 0.06% 153
2023
Q4 		$101K Buy
+3,100
New +$85.1K 0.08% 134

Other funds holding CORT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Planning Capital Management Corporation's CORT Position: Q3 2024 in Review

Planning Capital Management Corporation reduced its Corcept Therapeutics (CORT) stake by 65% in Q3 2024, selling an estimated $71.1K and leaving 1,100 shares worth $50.9K. The position accounts for 0.03% of the portfolio, ranked #179.

Planning Capital Management Corporation first reported a position in CORT in Q4 2023 and has held it in 4 quarters since. The position peaked at $101K in Q2 2024. 321 funds tracked by Wall St. Rank hold CORT as of Q3 2024.

  • Planning Capital Management Corporation held 1,100 shares of Corcept Therapeutics worth $50.9K as of Q3 2024.
  • Planning Capital Management Corporation sold 2,000 Corcept Therapeutics shares in Q3 2024, an estimated $71.1K.
  • Corcept Therapeutics made up 0.03% of Planning Capital Management Corporation's portfolio in Q3 2024, its #179 holding.
  • Planning Capital Management Corporation first reported a position in Corcept Therapeutics in Q4 2023 and has held it in 4 quarters since.
  • Planning Capital Management Corporation's Corcept Therapeutics position peaked at $101K in Q2 2024.
  • 321 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2024.

Based on Planning Capital Management Corporation's 13F filing for Q3 2024, filed 6 Nov 2024.